This script search US Code. View Rule
Menu Item - Home
Menu Item - Agenda Main page
Menu Item - Historical Agenda
Menu Item - Historical Agenda
Menu Item - Agenda Search
Menu Item - EO Dashboard
Menu Item - Reg Review
Menu Item - EO Agency lists
Menu Item - EO Search
Menu Item - EO Historical Reports
Menu Item - Review Counts
Menu Item - OIRA Letters
Menu Item - EOM 12866 Search
Menu Item - EO XML Reports
Menu Item - ICR Dashboard page
Menu Item - ICR Main page
Menu Item - ICR Search
Menu Item - ICR XML Reports
Menu Item - FAQ
Menu Item - Additional Resources
Menu Item - Contact Us
Search: Agenda Reg Review ICR
       Search

View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/FDA RIN: 0910-AC48 Publication ID: Fall 2003 
Title: Applications for FDA Approval To Market a New Drug: Patent Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug Applications 
Abstract: The final rule would clarify the types of patents for which information must or must not be submitted to FDA. The final rule would also revise the patent declaration to make it more detailed. The rule would also revise the regulations regarding the approval date for certain abbreviated new drug applications or "505(b)(2) applications" by stating that there is only one opportunity for a 30-month stay in the approval date of an ANDA or 505(b)(2) application. 
Agency: Department of Health and Human Services(HHS)  Priority: Economically Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Completed Actions 
Major: Yes  Unfunded Mandates: Private Sector 
CFR Citation: 21 CFR 314.52(a)(3); 21 CFR 314.53(b); 21 CFR 314.53(c)(1); 21 CFR 314.53(c)(2); 21 CFR 314.95(a)(3) 
Legal Authority: 21 USC 321; 21 USC 331; 21 USC 351 to 353; 21 USC 355; 21 USC 355a; 21 USC 356; 21 USC 356a; 21 USC 356b; 21 USC 356c; 21 USC 371; 21 USC 374; 21 USC 379e 
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  10/24/2002  67 FR 65448 
NPRM Comment Period End  12/23/2002   
Final Rule  06/18/2003  68 FR 36676 
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: No  Federalism: No 
Included in the Regulatory Plan: No 
Agency Contact:
Jarilyn Dupont
Director of Regulatory Policy
Department of Health and Human Services
Food and Drug Administration
WO Building 32, Room 4245, 10903 New Hampshire Avenue,
Silver Spring, MD 20993
Phone:301 796-4830
Fax:301 847-3541
Email: jarilyn.dupont@fda.hhs.gov

 
About Us   Vertical Spacer Spacer Related Resources   Vertical Spacer Spacer Disclosure   Vertical Spacer Spacer Accessibility   Vertical Spacer Spacer Privacy Policy   Vertical Spacer Spacer Contact Us